Overview

Phase 1 Trial of Oral Ixabepilone

Status:
Terminated

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants with advanced cancer

Phase:

Phase 1

Details

Lead Sponsor:

R-Pharm

Treatments:

Epothilones